Kava ban highly questionable: A brief summary of the main scientific findings presented in the "in depth investigation on EU member states market restrictions on kava products"

Seminars in Integrative Medicine

Volumn 1, Issue 4, 2003, Pages 199-210

  Gruenwald, Joerg ^a   Skrabal, Juergen ^a  

^a PhytoPharm Consulting   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; DEMETHOXYYANGONIN; DIHYDROKAWAIN; DIHYDROMETHYSTICIN; KAVA EXTRACT; KAWAIN; LACTONE DERIVATIVE; METHYSTICIN; OROTATE MAGNESIUM; OXAZEPAM; VITIS VINIFERA EXTRACT; YANGONIN;

ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; DROWSINESS; DRUG APPROVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG STRUCTURE; EUROPEAN UNION; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HERBAL MEDICINE; HUMAN; ICHTHYOSIS; KAVAFORM; LIVER TOXICITY; MENTAL STRESS; META ANALYSIS; NONHUMAN; PHARMACODYNAMICS; PIPER METHYSTICUM; RESTLESSNESS; SYSTEMATIC REVIEW; TREMOR;

EID: 5444262664     PISSN: 15431150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sigm.2004.01.001     Document Type: Review

References (77)

1. Lebot V Merlin M Lindstrom M Kava: The Pacific Drug 1992 Yale University Press New Haven and London
2. BfArM (Federal Institute for Drugs and Medicinal Products): www.bfarm.de/de/Arzneimittelam ℐcher/stufenpl/Besch-Kava-Final.pdf
3. He X.-G Lin L.-Z Lian L.-Z Electrospray high performance liquid chromatography-mass spectrometry in phytochemical analysis of kava (Piper methysticum) Extract Planta Med 63 1997 70-74
4. Boonen G Beck M.-A Häberlein H Contribution to the quantitative and enantioselective determination of kavapyrones by high-performance liquid chromatography on ChiraSpher NT material J Chromatogr B 702 1997 240-244
5. Duffield A.M Lidgard R.O Analysis of kava resin by gas chromatography and electron impact and methane negative ion chemical ionization mass spectrometry Biomed Environ Mass Spectrom 13 1986 621-626
6. Duffield A.M Lidgard R.O Low G.K.-C Analysis of the constituents of Piper methysticum by gas chromatography methane chemical ionization mass spectronomy Biomed Environ Mass Spectrom 13 1986 305-313
7. Häberlein H Boonen G Beck M.-A Piper methysticum: Enantiomeric separation of kavapyrones by high performance liquid chromatography Planta Med 63 1997 63-65
8. Hänsel R Keller K Rimpler H et al. Hagers Handbuch der Pharmazeutischen Praxis (Eds.), (ed 5) 1994 191-221 Springer Publishers Berlin, Germany Monograph: Piper Vol. 6: Drogen P-Z
9. Hänsel R Lazar J Kawapyrone: Inhaltsstoffe des Rauschpfeffers in pflanzlichen Sedativa125 DAZ 1985 2056-2058
10. Hänsel R Woelk H Spektrum Kava-Kava (ed 2) 1994 Aesopus Publishers Basel, Switzerland
11. Lechtenberg M Quandt B Kohlenberg F.-J et al. Qualitative and quantitative micellar electrokinetic chromatography of kavalactones from dry extracts of Piper methysticum Forst and commercial drugs J Chromatogr A 848 1999 457-464
12. Singh Y.N Kava: An overview J Ethnopharm 37 1992 13-45
13. Meyer H.J Pharmakologie der wirksamen prinzipien des Kawa-Rhizoms (Piper methysticum Forst) Arch Int Pharmacodyn 138 1962 505-536
14. Meyer H.J Meyer-Burg J Hemmung des Elektrokrampfes durch die Kawa-Pyrone Dihydromethysticin und Dihydrokavaine Arch Int Pharmacodyn 148 1964 97-110
15. Jamieson D.D Duffield P.H Cheng D et al. Comparison of the central nervous system activity of the aqueous and lipid extract of kava (Piper methysticum) Arch Int Pharmacodyn 301 1989 66-80
16. Jamieson D.D Duffield P.H Positive interactions of ethanol and kava resin in mice Clin Exp Pharm Physiol 17 1990 509-514
17. Hapke H.J Sterner W Heisler E et al. Toxicological studies with kavaform Il Farmaco Ed Pr 26 1971 692-720
18. Singh Y Devkota A Aqueous kava extracts do not affect liver function test in rats Planta Med 69 2003 496-499
19. Teschke R Gaus W Loew D Kava extract: Safety and risks including rare hepatotoxicity Phytomedicine 10 2003 440-446
20. Denham A McIntyre M Whitehouse J Kava-the unfolding story: Report on a work in progress J Alternative Complementary Med 8 2002 237-263
21. Cox P TenBruggencate J Scholar disputes warnings on kava 2002 Honolulu Advertiser April 22
22. Bhate H Gerster G Gracza E Orale Prämedikation mit Zubereitungen aus Piper methysticum bei operativen Eingriffen in Epiduralanästhesie Erfahrungsheilk 6 1989 339-345
23. De Leo V La Marca A Morgante G et al. Evaluation of combining kava with hormone replacement therapy in the treatment of postmenopausal anxiety Maturitas 39 2000 185-188
24. Gastpar M Klimm H Treatment of anxiety, tension and restlessness states with kava special extract WS 1490 in general practice: A randomized, placebo-controlled, double-blind multicenter trial Phytomedicine 10 2003 631-639
25. Kinzler E Krömer J Lehmann E Wirksamkeit eines Kava-Spezial-Extraktes bei Patienten mit Angst-, Spannungs- und Erregungszuständen nicht-psychotischer Genese Arzneimittelforschung 41 1991 584-588
26. Lehmann E Kinzler E Friedemann J Efficacy of a special kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin: A double-blind placebo-controlled study of four weeks treatment Phytomedicine 3 1996 113-119
27. Lehrl S Clinical efficacy of kava extract WS® 1490 in sleep disturbances associated with anxiety disorders: Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial J Affect Discord 78 2004 101-110
28. Malsch U Kieser M Efficacy in the treatment of non-psychotic anxiety, following pre-treatment with benzodiazepines Psychopharmacology 157 2001 277-283
29. Singh N Ellis C Sharp I et al. A 4-week, randomized, double-blind, placebo-controlled study to investigate the effectiveness and safety of Kavatrol® was conducted in a non-clinical sample with anxiety and stress 1997 Natrol
30. Volz H.-P Kieser M Kava-kava extract WS 1490 versus placebo in anxiety disorders: A randomized placebo-controlled 25-week outpatient trial Pharmacopsychiatry 30 1997 1-5
31. Warnecke G Pfaender H Gerster G et al. Wirksamkeit von Kava-Kava-Extrakt beim klimakterischen Syndrom Z Phytother 11 1990 81-86
32. Warnecke G Psychosomatische Dysfunktionen im weiblichen Klimakterium Fortschr Med 109 1991 119-122
33. Woelk H Kapoula O Lehrl S et al. Behandlung von Angst-Patienten. Doppelblindstudie: Kava-Spezialextrakt versus Benzodiazepine Z Allg Med 69 1993 271-277
34. Commission E Monograph: Piperis methystici rhizoma (Kava-Kava-Wurzelstock) Federal Legal Gazette (Bundesanzeiger) No 101, 01.06.1990 Translation in Blumenthal M Busse W.R Goldberg A et al. (Eds) The Complete German Commission E Monographs 1998 156-157 American Botanical Council Austin, TX
35. Hofmann R Winter U Therapeutische Möglichkeiten mit Kava-Kava bei Angsterkrankungen Psycho 22 suppl 1996 51-53
36. Lehrl S Woelk H Kava-Spezialextrakt WS 1490 bei Patienten mit Angstsymptomatik Fortschritte der Medizin 120 2002 61-65
37. Neto J Efficácia e tolerabilidade do extracto de kava-kava WS 1490 em estados de ansiedade. Estudo multicêentrico brasileiro Rev Bras Med 56 1999 280-284
38. Scherer J Kava-Kava extract in anxiety disorders: An outpatient observational study. Adv Ther 15 1998 261-269
39. Siegers C.-P Honold E Krall B et al. Ergebnisse der Anwendungsbeobachtung L 1090 mit Laitan Kapseln Ärztl Forsch 39 1992 7-11
40. Spree M.H Croy H.-H Antares: ein standardisiertes Kava-Kava-Präparat mit dem Spezialextract KW 1491 Der Kassenarzt 17 1992 44-51
41. Strahl S Ehret V Dahm H et al. Nekrotisierende Hepatitis nach Einnahme Pflanzlicher Heilmittel Dtsch Med Wochenschr 123 1998 1410-1414
42. Waller D Report on Kava and Liver Damage 2003 American Herbal Products Association Silver Spring, MD
43. Schmidt M Nahrstedt A Is kava hepatotosxic? DAZ 142 2002 58-63
44. Schmidt M, Nahrstedt A: Is kava really hepatotoxic? www.uni-muenster.de/chemie/pb/kava/analyse.html
45. Teschke R Gaus W Loew D Kava extract: Safety and risks including rare hepatotoxicity Phytomedicine 10 2003 440-446
46. Hänsel R Beiersdorff H.-U Zur Kenntnis der sedativen Prinzipien des Kawa-Rhizoms Arzneim-Forsch/Drug Res 9 1959 581-585
47. Kretzschmar R Teschendorf H.-J Pharmakologische Untersuchungen zur sedativ-tranquilisierenden Wirkung des Rauschpfeffers (Piper methysticum Forst) Chem Z 98 1974 24-28
48. Holm E Staedt U Heep J et al. Untersuchungen zum Wirkprofil von d,l-Kavaine Arzneim-Forsch/Drug Res 41 1991 673-683
49. Capasso A Calignano A Synergism between the sedative action of kava extract and d,l-kavaine Acta Ther 14 1988 249-256
50. Capasso A Pinto A Experimental investigations of the synergistic-sedative effect of passiflora and kava Acta Ther 21 1995 127-140
51. Meyer H.J Kretzschmar R Kawa-Pyrone: Eine neuartige Substanzgruppe zentraler Muskelrelaxantien vom Typ des Mephenesins Klin Wochenschr 44 1966 902-903
52. Kretzschmar R Teschendorf H.J Ladous A et al. On the sedative action of the kava rhizome Acta Pharm Toxicol 29 Suppl 4 1971 26
53. Seitz U Ameri A Pelzer H et al. Relaxation of evoked contractile activity of isolated guinea-pig ileum by (±)-kavaine Planta Med 63 1997 303-306
54. Klohs M.W Keller F Williams R.E et al. A chemical and pharmacological investigation of Piper methysticum Forst J Med Pharm Chem 1 1959 95-103
55. Meyer H.J Untersuchungen über den antikonvulsiven Wirkungstyp der Kawa-Pyrone Dihydromethysticin und Dihydrokavaine mit Hilfe chemisch induzierter Krämpfe Arch Int Pharmacodyn 150 1964 118-131
56. Kretzschmar R Meyer H.J Vergleichende Untersuchung über die antikonvulsive Wirksamkeit der Pyronverbindungen aus Piper methysticum Forst Arch Int Pharmacodyn 177 1969 261-277
57. Kretzschmar R Meyer H.J Teschendorf H.J et al. Antagonistische Wirkung natürlicher 5,6-hydrierter Kawa-Pyrone auf die Strychninvergiftung und den experimentellen lokalen Tetanus Arch Int Pharmacodyn 182 1969 251-268
58. 6-arylsubstituierter 4-Methoxy-α-pyrone vom Typ der Kawa-Pyrone Arzneim-Forsch/Drug Res 19 1969 617-623
59. Schmitz D Zhang C.L Chatterjee S.S et al. Effects of methysticin on three different models of seizure like events studied in rat hippocampal and entorhinal cortex slices Naunyn-Schmiedebergs Arch Pharmacol 351 1995 348-355
60. +-channels in synaptosomes prepared from rat cerebral cortex Neuropharmacol 34 1995 1133-1138
61. + channel receptor sites Eur J Pharmacol 315 1996 89-97
62. Brüggemann F Meyer H.J Die analgetische Wirkung der Kawa-Inhaltsstoffe Dihydrokawain und Dihydromethysticin Arzneim-Forsch/Drug Res 13 1963 407-409
63. Meyer H.J May H.U Lokalanaesthetische Eigenschaften natürlicher Kawa-Pyrone Klin Wochenschr 42 1964 407
64. Jamieson D.D Duffield P.H The antinociceptive actions of kava components in mice Clin Exp Pharm Physiol 17 1990 495-507
65. Duffield P.H Jamieson D.D Duffield A.M Effect of aqueous and lipid-soluble extracts of kava on the conditioned avoidance response in rats Arch Int Pharmacodyn 301 1989 81-90
66. Sällström Baum S Hill R Rommelspacher H Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats Prog Neuro-Psychopharmacol Biol Psychiatry 22 1998 1105-1120
67. Habs M Honold E Der psychoaktive Spezialextrakt WS 1490 aus dem Wurzelstock von Piper methysticum (Kava-Kava): Ein Report Forsch Komplementärmed 5 1994 208-215
68. Johnson D Frauenforf A Stecker K et al. Neurophysiologisches Wirkprofil und Verträglichkeit von Kava-Extract WS 1490 TW Neurol Psychiatry 5 1991 349-354
69. Heinze H.J Münthe T.F Steitz J et al. Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials Pharmacopsychiatry 27 1994 224-230
70. Münte T.F Heinze H.J Matzke M et al. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task Neuropsychobiology 27 1993 46-53
71. Geßner B Cnota P Untersuchung der Vigilanz nach Applikation von Kava-Kava-Extrakt, Diazepam oder Plazebo Z Phytother 15 1994 30-37
72. Emser W Bartylla K Verbesserung der Schlafqualität Zur Wirkung von Kava-Extrakt WS 1490 auf das Schlafmuster bei Gesunden TW Neurol Psychiatry 5 1991 636-642
73. Wiehl M Verkannte Angst TW Neurol Psychiatry 10 1996 496-499
74. Pittler M.H Ernst E Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis J Clin Psychopharmacol 20 2000 84-89
75. ESCOP European Scientific Cooperative on Phytomedicine Monograph: Piper methysticum: kava ESCOP Monographs (ed 2) 2003 Thieme Verlag Stuttgart, Germany
76. Commission E Erklärung von Mitgliedern der Kommission E zum Kava-Kava Verbot NaturaMed 17 2002 11-12
77. SGB V § 33a Abs. Gesetz zur Reform der gesetzlichen Krankenversicherung ab dem Jahr 2000 Artikel 1 Änderung des Fünften Buches Sozialgesetzbuch